HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Wellbutrin XL Ad Notes Suicidality Risk, Does Not Reflect “Black Box”

Executive Summary

A new GlaxoSmithKline television ad for the antidepressant Wellbutrin XL includes information about suicidality and mood changes
Advertisement

Related Content

FDA Takes Relaxed Stance On DTC Ads For Products With “Black Box”
FDA Takes Relaxed Stance On DTC Ads For Products With “Black Box”
FDA Awaits More Effexor Data Following U.K. Regulatory Changes
AstraZeneca Crestor Ad Defends Safety, Re-Asserts Superiority Claims
Antidepressant “Black Box” Presents Barrier To DTC Advertising
Antidepressant Suicide Risk In Eight Drug Labels; Pfizer Is Hold-Out
Antidepressant Suicide Risk In Eight Drug Labels; Pfizer Is Hold-Out
FDA Requests Antidepressant Labeling Add Suicidality Warning

Topics

Advertisement
UsernamePublicRestriction

Register

PS045186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel